In a 2026 Business Group on Health survey, nearly eight in 10 employers reported that GLP-1 drugs were raising their health care costs. More than half of those covering weight-management drugs expected significant clinical benefits, but few saw that evidence reflected in aggregate claims.
Timing creates a measurement problem. Total claims include both pharmacy and medical spending. When drug costs arrive immediately and savings arrive later, the upfront cost increase can make a working program look like it is failing.
GLP-1 costs can distort year-over-year results
To judge whether the program is working, trustees first need to know how much of the increase comes from GLP-1 drugs. In the International Foundation of Employee Benefit Plans’ 2026 survey, multiemployer and public plans reported that GLP-1 drugs for weight loss averaged 14.7% of total annual claims in 2025, compared with 11.4% for corporate plans. Mercer’s actuaries estimate that rising GLP-1 use accounted for a full percentage point of projected 2027 health benefit cost growth.
When one drug class makes up that share of total claims, its growth can drive the direction of the total. A trustee who reads only the bottom line might conclude that the care management program failed. However, the data underneath tells the opposite story.
Normalize GLP-1 spend before judging population health
The answer is to evaluate the same claims data through two distinct lenses. Total healthcare spending must remain the foundation of every financial review, as it determines overall plan costs and informs contribution decisions. At the same time, trustees need a clearer view of what is driving those costs by isolating the incremental impact of GLP-1 spending and independently evaluating trends in medical utilization and costs.
Separating GLP-1 spending for analytical purposes does not remove those expenses from the balance sheet. Rather, it provides trustees with a more accurate understanding of two important trends: how rapidly GLP-1 utilization and spending are increasing, and how other healthcare costs and utilization patterns are changing. This distinction helps trustees identify the underlying value of care management programs, even when rising GLP-1 expenditures temporarily offset measurable savings elsewhere.
The cost curve moves faster than the benefit curve
Aon tracked medical and pharmacy claims for more than 192,000 GLP-1 users between 2022 and 2025. Over time, their medical costs grew more slowly than those of matched nonusers. For members with diabetes, medical cost growth ran six percentage points lower at 30 months. For members using the drugs for weight loss, it ran three points lower at 18 months. Those improvements came after the first year of treatment, so a fund that reviews GLP-1 costs at the 12-month mark sees pharmacy spending before the slowdown Aon measured.
Mercer points to slow disease progression and employee turnover as reasons the immediate return remains uncertain for employers. Health funds start from a different position. Members stay in the same fund for longer and sometimes from childhood to elder years, so the fund paying for the first year of therapy is more likely to still cover that member when the savings arrive. An evidence-based therapy that raises near-term spending while improving long-term health deserves this fair measurement window.
Care management protects the investment
Coverage approval starts the work. In the Aon data, users who kept at least 80% adherence saw larger reductions in medical cost growth: nine points for diabetes and seven points for weight loss. Staying on therapy is the hard part. Prime Therapeutics data cited by Mercer found that only one in 12 members remained on a GLP-1 for obesity after three years.
Nurse-led care management coordinates the clinical and practical sides of GLP-1 therapy. Nurses educate members on use and side effects, coordinate between the member and provider if significant side effects are seen, and if the member stops GLP-1 use, the nurse assesses the why behind it and alerts the provider to look into alternative solutions. This coordination supports adherence, protecting the member’s health and the return the fund expects on its investment.
Measure what GLP-1 spending obscures
Trustees should look beyond total claims to measure the impact of care management on member health and utilization. In the first year, key indicators include emergency department visits and avoidable hospitalizations per 1,000 members, along with medication adherence among members prescribed GLP-1 therapies. Over time, those measures should expand to include changes in cardiovascular events and diabetes-related complications.
Evaluating these outcomes alongside total claims spending provides a more complete picture of whether care management is improving health, reducing avoidable utilization and delivering measurable value, even as GLP-1 costs continue to rise.
Separate short-term cost pressure from long-term value
What would a fund’s financial performance look like without the incremental impact of GLP-1 spending? Analyzing those costs separately from other medical and pharmacy claims helps trustees distinguish rising pharmaceutical expenditures from broader trends in healthcare utilization and spending.
For funds with active care management programs, this approach can reveal meaningful improvements in utilization, medication adherence and health outcomes that might otherwise be overshadowed by GLP-1 costs. It also recognizes that the longer-term clinical and financial benefits of these therapies may take years to materialize.
GLP-1 spending remains a significant and ongoing financial commitment. By examining both total claims and underlying utilization trends, trustees can make more informed coverage and investment decisions, balancing immediate cost pressures with the long-term health and financial interests of their members.
Photo: Eugene Mymrin, Getty Images
Also Read
- VA Study Links Updated COVID Vaccine to Lower Hospitalization Rates Among Nearly 1 Million Veterans
- Hims & Hers and Noom Launch Compounded Peptide Programs, Bringing Unapproved Wellness Treatments to Mainstream Telehealth
- Hone Health Raises $228 Million to Expand Personalized Longevity Care
- Two‑Year Results Sustain Clinical Benefits of Tau‑Targeted Diranersen in Alzheimer’s


